Pay in 4 interest-free payments of $5.28 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
SOUL was a randomized, double blind, parallel-group, placebo-controlled superiority trial that enrolled 9,650 adults with T2DM who had established atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), or both, to receive a maximum daily dose of 14 mg oral semaglutide or placebo
PubMed Corazza M, Arlotti E, Schettini N, Pacetti L, Bianchi A, Borghi A
Semaglutide is a GLP-1 receptor agonist initially developed to help regulate blood sugar levels in people with type 2 diabetes
Keep it Protected: Avoid direct contact with ice or freezing materials to prevent damage to the medication
US$ 26.54
US$ 22.05
US$ 25.82
US$ 22.99
